D. Boral Capital Reiterates “Buy” Rating for Can-Fite BioPharma (NYSE:CANF)

Can-Fite BioPharma (NYSE:CANF)‘s stock had its “buy” rating reaffirmed by equities research analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $10.00 price target on the stock.

A number of other research analysts have also weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday, November 12th. StockNews.com cut Can-Fite BioPharma from a “hold” rating to a “sell” rating in a research report on Friday, December 13th.

Can-Fite BioPharma Stock Up 5.5 %

CANF opened at $1.63 on Tuesday. Can-Fite BioPharma has a 52-week low of $1.29 and a 52-week high of $4.69. The company has a market cap of $5.75 million, a P/E ratio of -0.91 and a beta of 1.32. The firm’s 50-day moving average price is $1.88 and its 200-day moving average price is $2.36.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC raised its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the period. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. 21.00% of the stock is currently owned by institutional investors and hedge funds.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.